Nektar Therapeutics (NKTR) Q2 FY26 Earnings Call

Phase 3 execution is funded, but pivotal atopic dermatitis data remain nearly two years away.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-13
Length55 minutes
EPS$-1.23
EPS consensus$-2.06
Revenue$10.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All NKTR earnings ยท Back to NKTR overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.